论文部分内容阅读
目的 探讨重组人肝再生增强因子 (hALR)对肝纤维化大鼠血清透明质酸浓度的影响。方法 建立四氯化碳中毒性及人血白蛋白免疫损伤性两种大鼠肝纤维化模型。模型完成后予不同剂量hALR( 5 0 μg·kg-1·d、10 μg·kg-1·d)治疗。在不同的时间点留取大鼠血清标本 ,测定透明质酸浓度。结果 在两种模型中hALR治疗组大鼠血清透明质酸浓度在治疗过程中的不同阶段(治疗 1、2个月 )均明显低于模型组 (四氯化碳模型分别为 34 0 .7± 32 .1、2 34 .1± 19.5 ;人血白蛋白模型分别为 366.5± 32 .3、2 87.3± 30 .1)。高剂量hALR组大鼠血清透明质酸浓度 (四氯化碳模型分别为 2 0 3.3± 15 .5、134 .1± 9.8;人血白蛋白模型分别为 2 18.9± 15 .8、14 3.1± 8.7)均明显低于低剂量组 (四氯化碳模型分别为 2 73.3± 13.4、186.6± 11.3;人血白蛋白模型分别为 2 76.1± 2 3.4、198.7± 11.5 )。结论 重组人肝再生增强因子可降低肝纤维化大鼠血清透明质酸含量。
Objective To investigate the effect of recombinant human augmenter of liver regeneration (hALR) on the concentration of serum hyaluronic acid in rats with hepatic fibrosis. Methods To establish carbon tetrachloride toxic and human serum albumin immunostaining two kinds of rat liver fibrosis model. After the model was completed, different doses of hALR (50 μg · kg-1 · d, 10 μg · kg-1 · d) were treated. Rat serum samples were taken at different time points and hyaluronic acid concentrations were determined. Results In the two models, serum hyaluronic acid concentrations in the hALR-treated rats were significantly lower than those in the untreated group (1,27 months and 1,24 months, respectively) 32.1, 34.1 ± 19.5; human serum albumin models were 366.5 ± 32.3, 2 87.3 ± 30.1, respectively). Serum hyaluronic acid concentrations in high-dose hALR rats were 20.3 ± 15.5 and 134.1 ± 9.8, respectively, while those of human serum albumin were respectively 2 18.9 ± 15 and 14 3.1 ± 8.7) were significantly lower than the low dose group (carbon tetrachloride model were 2 73.3 ± 13.4,186.6 ± 11.3; human serum albumin model were 76.1 ± 2 3.4,198.7 ± 11.5). Conclusion Recombinant human augmenter of liver regeneration can reduce the content of serum hyaluronic acid in rats with hepatic fibrosis.